{"name":"Marinus Pharmaceuticals","slug":"marinus","ticker":"MRNS","exchange":"NASDAQ","domain":"marinuspharma.com","description":"Marinus Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for the treatment of epilepsy and other neurological disorders. The company's lead product candidate, ganaxolone, has shown promise in treating various forms of epilepsy. Marinus Pharmaceuticals has a strong pipeline of products in development, with a focus on addressing unmet medical needs in the neurology space. As a result, the company is well-positioned to capitalize on the growing demand for effective treatments in this area.","hq":"Radnor, PA","founded":0,"employees":"","ceo":"Scott Braunstein","sector":"Neurology / Epilepsy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":52000000,"revenueGrowth":21.6,"grossMargin":0,"rdSpend":99388000,"netIncome":-141405000,"cash":170908000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2022-01-01","label":"Ztalmy first approved","drug":"Ztalmy","drugSlug":"ganaxolone","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"ganaxolone patent cliff ($0.0B at risk)","drug":"ganaxolone","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ztalmy","genericName":"GANAXOLONE","slug":"ganaxolone","indication":"Seizures associated with CDKL5 deficiency disorders","status":"marketed"}]}],"pipeline":[{"name":"Ztalmy","genericName":"GANAXOLONE","slug":"ganaxolone","phase":"marketed","mechanism":"Ztalmy works by enhancing the activity of the GABA A receptor, a key player in regulating the activity of neurons in the brain.","indications":["Seizures associated with CDKL5 deficiency disorders"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Marinus Pharmaceuticals Announces FDA Approval of Ganaxolone for the Treatment of CDKL5 Deficiency Disorder","summary":"The FDA has approved ganaxolone for the treatment of CDKL5 deficiency disorder, a rare form of epilepsy.","drugName":"ganaxolone","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Marinus Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"Marinus Pharmaceuticals reported its third quarter 2023 financial results, with a net loss of $14.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-18","type":"deal","headline":"Marinus Pharmaceuticals Announces Collaboration with the Epilepsy Foundation","summary":"Marinus Pharmaceuticals has entered into a collaboration with the Epilepsy Foundation to raise awareness about epilepsy and promote the development of new treatments.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5uNGlxdzhMeGpSSlIwZHZoT1B1UExEX1VTcmlQN083V2dMalp6RmxCWmh2MFp1MkR6X3lYLUxjWHluUXRkVzdNQVpoQTdiSW44YjVJ?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"MRNS Stock Price, News & Analysis - Stock Titan","headline":"MRNS Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPWnY5anRQYkJXNTllakVqQVJmZG9YZ1pjZkd5SHh6MFRGMkZwc1IxNm5zdVlYQmU2YVI0ZzBROFRLOVlnMUMxejlJemQxdFFfSHRibDdnMHF2eXhzSG5HQk9WQUdzR29KSjh5Q2lvNlhyakRpTW5Jd0kzV0YtRnZaZE1fM0VUa0ZNNTVIM3h2ZW81dzA?oc=5","date":"2025-01-06","type":"deal","source":"The Pharma Letter","summary":"Immedica acquires Marinus in $151 million deal - The Pharma Letter","headline":"Immedica acquires Marinus in $151 million deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQM0FnOXZRTzJwVnVfUzNJMTQ0UFpXakx2c1BPblVkRFhfN2xJcDlVSlhqMERiWGplLU1sTjBvNUZHREU1WDY4aGVycGt1Y3ZUSEFfUU42R0JwU1VaOHhDblhVNlFEaW0xclFLNThSZV93ZldxU2ZLSy1kcUx3ZHo5c2NpcGQ0bFNCNWNsSlV4b0h1d3BwMVIyZW1QRUlOVU02Y2E3dHFkSV8yUnM0clJ0NFRKVWxwQTVUU0tQWTAwQmxGYXM5LVBKT25lRQ?oc=5","date":"2024-12-30","type":"deal","source":"Business Wire","summary":"Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. - Business Wire","headline":"Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOazFLZTJJdlJSZHQ0ZkluSGVHQmdYUlBSNXJfSksxa2p5aktVcGV3R3N5VVlsajVFRFE4bk5Nd3NxTUN6ZnJRVjFyRnp0RjhSMnBGV3ItZzdZdkg4YkRySTZvY3VqRTdxQkpfMU9zSVNKUWluZTNleUhFTkJoMXhXb2hXZ083UQ?oc=5","date":"2024-12-30","type":"pipeline","source":"Yahoo Finance","summary":"Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40% - Yahoo Finance","headline":"Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOelhLbXljSnhMRld2NVFjUERyVFlnYkEwcTBuaXFTa3NTYUN3NVBoYjlkWVU1dDc4NUQxVV9zTFpTWlBLUDJxYmRCeDBlSlJfaFVpekVObkVSQ1dWY245UzBPMkRkbHQtLVM0MExnUmtFSEpNaHVUTEc4Mk9heGYwRHAzRDE0UmdiM2ZSYnBYQ1c0M2poSktUVnVRWGNLYXhkUzdOdTRXNjdzQUxUN0JSOU5jQWMzdlBfSkdGVWE0MEZueURnT3R6Z25BaXAyUnEwdUtYLVR4eno3NmYwbVByRGF2S1ZTb3dzZHc?oc=5","date":"2024-11-12","type":"earnings","source":"Business Wire","summary":"Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire","headline":"Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxQNVBsUDVlZjR2QkpFUDNxTGJmY0E0X2dUNmFkWVpoZE13S0psVlpoRzlMQ0QzbV9Db29ONkhGZi1reW5FRWp2REF6d0hrU2xEOW5jRHdzOFRQMTB0Skg4a0VmN1BFdlVDa01aelJQR0M1UWlzaUxhU2tlMi1TQ0p2T1RoaWIxdldmLU1pbGRjZm9JNU03VEtvSmx2SDE4dzMzYjk3TG5jQThoaDJnaU5nOXA5OXd4VkhfNWVPcmllVWViZWNEWFV0MFptZXR3NTFESV96UDd1UXBZSHpWNEg4WVdNRS1JNjRJZEhNblkzUDFDUF85TTZuVDN5NzduR3gxYWVEMUlSLWE4WFNnSk16c1pIb1RfNllNdVJmY1JTNGV4eUk?oc=5","date":"2022-07-28","type":"pipeline","source":"ir.marinuspharma.com","summary":"Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 Deficiency Disorder - ir.marinuspharma.com","headline":"Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 Defi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE5JOFVPRTR2UjdkMEpuR3ZBVk1QVlZkdnlXbzJ2emM0LUxzLVVvUGI5Um1GczNXYm9hQUhlNkJkQzVTZ1pMd21DUFZUbExjdw?oc=5","date":"2020-09-13","type":"deal","source":"Stock Titan","summary":"Latest MRNS News - Immedica to Acquire Biopharmaceutical Compa... - Stock Titan","headline":"Latest MRNS News - Immedica to Acquire Biopharmaceutical Compa...","sentiment":"neutral"}],"patents":[{"drugName":"ganaxolone","drugSlug":"ganaxolone","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Ultragenyx Pharmaceutical Inc.","Zogenix, Inc.","GW Pharmaceuticals plc"],"therapeuticFocus":["Epilepsy","Neurology"],"financials":{"source":"sec_edgar+yahoo","revenue":30989000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":30989000,"period":"2023-12-31"},{"value":25478000,"period":"2022-12-31"},{"value":25478000,"period":"2022-12-31"},{"value":15345000,"period":"2021-12-31"},{"value":15345000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":99388000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-141405000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":170908000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}